Medical Advocates
HIV Protease Inhibitors
  Resistance/Cross Resistance  
Mutations
 Resistance: General Reports
 Cross Resistance




 		  
Protease Inhibitors Main Page   Main New/Newsworthy Home    

Last Update:  October 18, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Mutations
 
     Journal Papers, Abstracts, and Commentaries
 
 
Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy
patients.
Kapoor A, Shapiro B, Shafer RW,et al
 Retrovirology. 2008 Jan 25;5(1):7
 Abstract
 
Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-
Conferring Mutations in NNRTI- or PI-Treated Patients.
 Maggiolo F, Airoldi M, Kleinloog HD, et al
 HIV Clin Trials. 2007 Sep-Oct;8(5):282-92
 Abstract

Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term
on-suppressive protease inhibitor treatment.
Kagan RM, Cheung PK, Huard TK, Lewinski MA. 
Antiviral Res. 2006 Mar 23;
Abstract
 
  Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1
Protease following Different Protease Inhibitor Treatments.
Wu TD, Schiffer CA, Gonzales MJ, et al.
J Virol 2003 Apr 15;77(8):4836-4847
Abstract
Resistance: General Reports
 

     Journal Papers, Abstracts, and Commentaries
 

 
Population trends in the prevalence and patterns of protease resistance related to exposure to
unboosted and boosted protease inhibitors.
Dunn D, Geretti AM, Green H, et al  
Antivir Ther. 2008;13(6):771-7.
 Abstract
 
Increased Resilience to the Development of Drug Resistance with Modern Boosted Protease Inhibitor-Based
Highly Active Antiretroviral Therapy.
Lima VD, Gill VS, Yip B, et al 
J Infect Dis. 2008 May 22.
 Abstract
 
Protease inhibitor resistance update: where are we now?
Kim R, Baxter JD.
AIDS Patient Care STDS. 2008 Apr;22(4):267-77.
 Abstract
 
HIV-1 protease inhibitors: effects on HIV-2 replication and resistance.
Menéndez-Arias L, Tözsér J.
Trends Pharmacol Sci. 2007 Dec 2
Abstract
 
Protease inhibitor resistance in HIV-infected patients: Molecular and clinical perspectives.
Martinez-Cajas JL, Wainberg MA.  
Antiviral Res. 2007 Jul 16;
 Abstract
 
Impact of HIV protease inhibitor resistance in treatment-naive populations in the united states.
Hicks C. 
AIDS Read. 2005 Dec;15(12):683-6,
Abstract
 
Comparison of HIV Type 1 Protease Inhibitor Susceptibility Results in Viral Samples
Analyzed by Phenotypic Drug Resistance Assays and by Six Resistance Algorithms:
An Analysis of a Subpopulation of the CHORUS Cohort.
Ross L, Boulme R, Fusco G, et al
 AIDS Res Hum Retroviruses. 2005 Aug;21(8):696-701.
 Abstract

Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in
patients who are chronically infected with human immunodeficiency virus type 1.
 Martinez-Picado J, Wrin T, et al 
J Virol. 2005 May;79(10):5907-13.
Abstract

Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and
relationship with drug resistance.
 Masquelier B, Pereira E, Peytavin G, et al 
J Clin Virol. 2005 May;33(1):75-8
 Abstract
 
Determining and Overcoming Resistance to HIV Protease Inhibitors.
Prejdova J, Soucek M, Konvalinka J.
Curr Drug Targets Infect Disord. 2004 Jun;4(2):137-52.
 Abstract
 
Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.
 Watkins T, Resch W, Irlbeck D, Swanstrom R.
Antimicrob Agents Chemother 2003 Feb;47(2):759-69
 Abstract

CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients
who remain viremic despite long-term treatment with protease inhibitor-based therapy.
 Deeks SG, Hoh R, Grant RM, et al.
 J Infect Dis 2002 Feb 1;185(3):315-23
 Abstract

Development and significance of resistance to protease inhibitors in HIV-1-infected adults under
triple-drug therapy in clinical practice.
Romano L, Venturi G, Giomi S, et al.
 J Med Virol 2002 Feb;66(2):143-50
 Abstract

FULL-TEXT  ARTICLE
 Computational study of protein specificity: the molecular basis of HIV-1 protease
drug resistance.
 Wang W, Kollman PA.
 Proc Natl Acad Sci U S A 2001 Dec 18;98(26):14937-42
Paper
 

     Conference Reports, Abstracts, and Posters

 
Analysis of the influence of HIV-1 protease-specific T-cells on the sequence of HIV-1-protease
and the development of drug resistance
 S Muller, B Schatz, Kismann, et al
 (8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
Unexplained Protease Inhibitor (PI) Resistance in Clinical Isolates Lacking Known Primary
PI Mutations
N T. PARKIN, C. CHAPPEY, E. LAM, C. J. PETROPOULOS; et al 
(45 ICAAC)
 Abstract
 
MDR1 Genotype May Influence CD4+ T-cell P-glycoprotein Activity in HIV-1-infected
Persons Receiving Protease Inhibitors
 T Hulgan, J Donahue, R Kim,et al
(11 CROI)
Abstract
Cross Resistance
 
     Journal Papers, Abstracts, and Commentaries
 
  Molecular Basis for Increased Susceptibility of Isolates with Atazanavir Resistance-
Conferring Substitution I50L to Other Protease Inhibitors.
 Yanchunas J Jr, Langley DR, et al   
Antimicrob Agents Chemother. 2005 Sep;49(9):3825-32.
Abstract  
 
     Conference Reports, Abstracts, and Posters
 
  Distinct cross-resistance profiles of the new protease inhibitors (PI) Amprenavir,
Lopinavir, and Atazanavir in a panel of clinical samples
B Schmid, T Schnell , G Moschik, et al
(1st European HIV Drug Resistance Workshop)
 Abstract
 
Protease inhibitors cross-resistance
F Maggiolo, A Callegaro, D Ripamonti, et al.
(1st European HIV Drug Resistance Workshop)
 Abstract

Protease Inhibitors Main Page   Main New/Newsworthy Home    

Protease Inhibitors Resistance/Cross Resistance